ETPrime

Aurobindo Pharma Share Price

  • 1,040.20-3.90 (-0.38%)
  • Volume: 4,15,761
  • Closed
  • Last Updated On: 08 Sep, 2025, 03:56 PM IST
  • 1D
  • 1W
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Loading...
Aurobindo Pharma Share Price
  • 1,040.20-3.90 (-0.38%)
  • Volume: 4,15,761
Advertisment
Stock Recommendations

  • Potential
    Upside

  • 1 Year
    Target

BUY

Mean Recos by
26 Analysts

1

4

0

11

10

Strong Sell

Sell

Hold

Buy

Strong Buy

Unlock Potential Upside
Stock Reports Plus

/10

Stock Score

View Report
Earnings
Fundamentals
Relative Valuation
Risk
Price Momentum
No Rating (NR)
Negative
Neutral
Positive
Unlock Stock Score

Aurobindo Pharma share price insights

  • Company has spent 1.44% of its operating revenues towards interest expenses and 14.11% towards employee cost in the year ending Mar 31, 2025. (Source: Consolidated Financials)

  • Weekly stochastic crossover appeared on week ending Sep 05, 2025. Average price decline of -8.18% within 7 weeks of this signal in last 10 years.

  • Aurobindo Pharma Ltd. share price moved down by -0.38% from its previous close of Rs 1,044.10. Aurobindo Pharma Ltd. stock last traded price is 1,040.20

    Share PriceValue
    Today/Current/Last1,040.20
    Previous Day1,044.101,044.40

InsightsAurobindo Pharma

    Do you find these insights useful?

    • hate it

    • meh

    • love it

    Key Metrics

    PE Ratio
    (x)    		17.81
    EPS - TTM
    (₹)    		58.39
    MCap
    (₹ Cr.)    		60,414.98
    Sectoral MCap Rank
    		11
    PB Ratio
    (x)    		1.86
    Div Yield
    (%)    		0.00
    Face Value
    (₹)    		1.00
    Beta

    Beta

    1 Month1.73
    3 Months1.31
    6 Months0.82
    1 Year1.06
    3 Years1.23

    		1.73
    VWAP
    (₹)    		1,043.44
    52W H/L
    (₹)
    1,592.00 / 1,010.00

    Aurobindo Pharma Share Price Returns

    1 Day-0.38%
    1 Week1.48%
    1 Month-0.18%
    3 Months-10.41%
    1 Year-32.34%
    3 Years91.88%
    5 Years32.28%

    ET Stock ScreenersTop Score Companies

    Check whether Aurobindo Pharma belongs to analysts' top-rated companies list?

    View Stock Screeners

    Aurobindo Pharma News & Analysis

    View all Aurobindo Pharma Share News & Announcements

    Aurobindo Pharma Share Recommendations

    Recent Recos

    BUY

    Current

    Mean Recos by 26 Analysts

    Strong
    Sell    SellHoldBuyStrong
    Buy
    • Target₹1330
    • OrganizationICICI Securities
    • ADD
    • Target₹1755
    • OrganizationHDFC Securities
    • BUY

    Analyst Trends

    RatingsCurrent1 Week Ago1 Month Ago3 Months Ago
    Strong Buy1010109
    Buy11111111
    Hold---1
    Sell4442
    Strong Sell1112
    # Analysts26262625
    View all Stock Recommendations

    Aurobindo Pharma Financials

    • Insights

      • Employee & Interest Expense

        Company has spent 1.44% of its operating revenues towards interest expenses and 14.11% towards employee cost in the year ending Mar 31, 2025. (Source: Consolidated Financials)
      Quarterly | AnnualJun 2025Mar 2025Dec 2024Sep 2024Jun 2024
      Total Income7,973.448,516.938,135.817,932.077,787.95
      Total Income Growth (%)-6.384.682.571.850.94
      Total Expenses6,670.817,034.636,819.076,612.216,351.63
      Total Expenses Growth (%)-5.173.163.134.10-0.50
      EBIT1,302.631,482.301,316.741,319.861,436.32
      EBIT Growth (%)-12.1212.57-0.24-8.117.83
      Profit after Tax (PAT)824.75903.47845.81817.38919.22
      PAT Growth (%)-8.716.823.48-11.081.15
      EBIT Margin (%)16.3417.4016.1816.6418.44
      Net Profit Margin (%)10.3410.6110.4010.3011.80
      Basic EPS (₹)14.2015.5614.5614.0015.69
      Quarterly | AnnualJun 2025Mar 2025Dec 2024Sep 2024Jun 2024
      Total Income2,931.942,845.972,970.892,947.252,525.41
      Total Income Growth (%)3.02-4.200.8016.70-16.29
      Total Expenses2,121.852,229.362,271.762,171.872,028.04
      Total Expenses Growth (%)-4.82-1.874.607.09-7.14
      EBIT810.09616.61699.13775.38497.37
      EBIT Growth (%)31.38-11.80-9.8355.90-40.29
      Profit after Tax (PAT)559.13408.17472.05537.53329.04
      PAT Growth (%)36.98-13.53-12.1863.36-43.14
      EBIT Margin (%)27.6321.6723.5326.3119.69
      Net Profit Margin (%)19.0714.3415.8918.2413.03
      Basic EPS (₹)9.637.038.139.215.62
      Quarterly | Annual FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
      Total Revenue32,345.5829,559.2525,145.9723,775.8425,155.47
      Total Revenue Growth (%)9.4317.555.76-5.488.01
      Total Expenses27,247.6024,970.2422,521.8020,243.8820,571.10
      Total Expenses Growth (%)9.1210.8711.25-1.595.46
      Profit after Tax (PAT)3,485.883,172.971,927.502,648.155,334.84
      PAT Growth (%)9.8664.62-27.21-50.3688.45
      Operating Profit Margin (%)17.5116.8211.1215.2618.80
      Net Profit Margin (%)10.9810.947.7511.2921.53
      Basic EPS (₹)59.8154.1632.9045.1991.05
      Quarterly | Annual FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
      Total Revenue11,261.4211,261.7013,226.0411,958.1316,413.54
      Total Revenue Growth (%)0.00-14.8510.60-27.1420.07
      Total Expenses8,902.978,858.7811,611.6910,245.9412,220.53
      Total Expenses Growth (%)0.50-23.7113.33-16.168.22
      Profit after Tax (PAT)1,746.791,954.141,230.411,454.713,112.91
      PAT Growth (%)-10.6158.82-15.42-53.2766.22
      Operating Profit Margin (%)23.6724.2813.5115.3126.67
      Net Profit Margin (%)15.9718.359.6112.8819.67
      Basic EPS (₹)29.9733.3521.0024.8353.13

      All figures in Rs Cr, unless mentioned otherwise

      View Details
    • Annual FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
      Total Assets49,784.9745,071.5139,889.9933,921.7233,853.99
      Total Assets Growth (%)10.4612.9917.590.2017.04
      Total Liabilities17,138.0415,220.7113,038.149,347.6711,925.00
      Total Liabilities Growth (%)12.6016.7439.48-21.61-1.58
      Total Equity32,646.9329,850.8026,851.8524,574.0521,928.99
      Total Equity Growth (%)9.3711.179.2712.0630.45
      Current Ratio (x)1.851.981.872.221.86
      Total Debt to Equity (x)0.240.210.180.100.23
      Contingent Liabilities2,349.813,323.111,813.211,145.451,083.17
      Annual FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
      Total Assets27,513.0625,153.9824,933.6521,600.9523,188.99
      Total Assets Growth (%)9.380.8815.43-6.8518.71
      Total Liabilities6,978.955,431.167,019.484,483.617,264.38
      Total Liabilities Growth (%)28.50-22.6356.56-38.2811.60
      Total Equity20,534.1119,722.8217,914.1717,117.3415,924.61
      Total Equity Growth (%)4.1110.104.667.4922.26
      Current Ratio (x)1.201.381.462.351.83
      Total Debt to Equity (x)0.230.140.230.110.25
      Contingent Liabilities1,329.982,053.57596.69277.611,337.36

      All figures in Rs Cr, unless mentioned otherwise

      View Details

    • Insights

      • Decrease in Cash from Investing

        Company has used Rs 1875.8 cr for investing activities which is an YoY decrease of 55.93%. (Source: Consolidated Financials)
      Annual FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
      Net Cash flow from Operating Activities3,924.622,434.522,386.755,016.483,328.92
      Net Cash used in Investing Activities-1,875.80-4,255.95-3,977.75-3,211.56598.69
      Net Cash flow from Financing Activities119.78800.421,814.41-2,969.27-1,364.81
      Net Cash Flow2,178.36-1,006.84229.76-1,167.402,583.09
      Closing Cash & Cash Equivalent5,563.793,385.434,392.274,162.515,329.91
      Closing Cash & Cash Equivalent Growth (%)64.35-22.925.52-21.9094.04
      Total Debt/ CFO (x)2.022.592.040.471.49
      Annual FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
      Net Cash flow from Operating Activities1,645.791,714.801,821.163,726.712,994.41
      Net Cash used in Investing Activities-2,065.90-159.96-3,459.68-1,613.51-2,648.73
      Net Cash flow from Financing Activities616.31-1,837.031,719.48-2,447.54-27.94
      Net Cash Flow211.94-273.8181.44-335.37316.23
      Closing Cash & Cash Equivalent295.2683.32129.6548.21383.58
      Closing Cash & Cash Equivalent Growth (%)254.37-35.73168.93-87.43545.32
      Total Debt/ CFO (x)2.811.642.270.491.32

      All figures in Rs Cr, unless mentioned otherwise

      View Details
    • Annual FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
      Return on Equity (%)10.6710.637.1810.7724.32
      Return on Capital Employed (%)15.8214.849.7313.8920.09
      Return on Assets (%)7.007.034.837.8015.75
      Interest Coverage Ratio (x)15.7622.0928.5496.7776.71
      Asset Turnover Ratio (x)0.670.680.670.690.79
      Price to Earnings (x)19.3420.1215.7514.819.69
      Price to Book (x)2.062.141.131.592.36
      EV/EBITDA (x)9.319.987.277.948.95
      EBITDA Margin (%)22.7122.0616.1320.0623.06
      Annual FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
      Return on Equity (%)8.509.906.868.4919.54
      Return on Capital Employed (%)12.2712.989.479.9225.69
      Return on Assets (%)6.347.764.936.7313.42
      Interest Coverage Ratio (x)12.5415.5518.83126.59164.22
      Asset Turnover Ratio (x)0.420.430.550.500.74
      Price to Earnings (x)38.6132.6824.6926.9516.61
      Price to Book (x)3.283.241.692.293.24
      EV/EBITDA (x)24.8423.4315.8719.1011.72
      EBITDA Margin (%)26.3926.6716.9218.9929.76

    Financial InsightsAurobindo Pharma

    • Income (P&L)
    • Cash Flow

      • Employee & Interest Expense

        Company has spent 1.44% of its operating revenues towards interest expenses and 14.11% towards employee cost in the year ending Mar 31, 2025. (Source: Consolidated Financials)

      • Decrease in Cash from Investing

        Company has used Rs 1875.8 cr for investing activities which is an YoY decrease of 55.93%. (Source: Consolidated Financials)

    Do you find these insights useful?

    • hate it

    • meh

    • love it

    Aurobindo Pharma Share Price Forecast

    • Get multiple analysts’ prediction on Aurobindo Pharma

      Stock Forecast Non Prime User
      • High, low, medium predictions for Price
      • Upcoming predictions for Revenue
      • Details about company earnings
      START FREE TRIAL

    • Get multiple analysts’ prediction on Aurobindo Pharma

      Stock Forecast Non Prime User
      • High, low, medium predictions for Price
      • Upcoming predictions for Revenue
      • Details about company earnings
      START FREE TRIAL

    • Get multiple analysts’ prediction on Aurobindo Pharma

      Stock Forecast Non Prime User
      • High, low, medium predictions for Price
      • Upcoming predictions for Revenue
      • Details about company earnings
      START FREE TRIAL

    Aurobindo Pharma Technicals

    • Bullish / Bearish signals for Aurobindo Pharma basis selected technical indicators and moving average crossovers.

      MACD Crossover

      Bullish signal on daily chart

      Appeared on: 5 Sep 2025

      Region: Negative

      Last 4 Buy Signals:19 Aug 2025
      Date10 days Gain/Loss %
      19 Aug 2025-1.07%
      29 Jul 20251.26%
      27 Jun 20256.78%
      17 Apr 20259.13%

      Average price gain of 4.13% within 10 days of Bullish signal in last 10 years

      Stochastic Crossover

      Bearish signal on weekly chart

      Appeared on: 5 Sep 2025

      Region: Oversold (Below 20)

      Last 4 Sell Signals:18 Jul 2025
      Date7 weeks Gain/Loss %
      18 Jul 2025-9.45%
      16 May 2025-10.21%
      11 Apr 20251.53%
      28 Feb 2025-2.57%

      Average price decline of -8.18% within 7 weeks of Bearish signal in last 10 years

      Show More
    • 44%
      Positive Movement since
      1st Jan 2005 on basis
      55%
      Negative Movement since
      1st Jan 2005 on basis
      Exclude

    • Pivot Levels

      R1R2R3PIVOTS1S2S3
      Classic1050.071059.931077.131042.731032.871025.531008.33

      Average True Range

      5 DAYS14 DAYS28 DAYS
      ATR21.0824.7227.09

    Aurobindo Pharma Peer Comparison

      • CHART
      • TABLE

      • Choose from Peers

          Choose from Stocks

          • 1D
          • 1W
          • 1M
          • 3M
          • 6M
          • 1Y
          • 5Y
          Loading...

        • Ratio Performance

          NAMEP/E (x)P/B (x)ROE %ROCE %ROA %Rev CAGR [3Yr]OPMNPMBasic EPSCurrent RatioTotal Debt/ Equity (x)Total Debt/ CFO (x)
          Aurobindo Pharma17.811.8510.6715.827.0010.6917.5111.0859.811.850.242.02
          Lupin24.045.1419.0721.2911.2311.3218.9714.5571.951.870.301.69
          Alkem Labs27.915.1318.0619.2912.247.5420.4317.09181.112.760.090.56
          Glenmark Pharma76.836.5411.8319.626.522.4914.857.8637.111.560.25-2.65
          Biocon126.461.764.686.041.7224.9017.609.368.461.140.824.37
          Add More
          Annual Ratios (%)

          Choose from Peers

          • Laurus Labs
          • Suven Pharma
          • Ipca Labs
          • Ajanta Pharma
          • Gland Pharma

          Choose from Stocks

            See All Parameters

          Peers InsightsAurobindo Pharma

            Do you find these insights useful?

            • hate it

            • meh

            • love it

            Aurobindo Pharma Shareholding Pattern

            • Loading...
              Showing Aurobindo Pharma Shareholding as on Jun 2025
              CategoryJun 2025Mar 2025Dec 2024Sep 2024
              Promoters51.8251.8251.8251.82
              Pledge17.0816.9217.8320.39
              FII14.3815.3316.2916.59
              DII26.9326.2325.2025.07
              Mutual Funds18.9618.2117.8118.53
              Others6.876.616.686.52
            • Showing Shareholding as on Jun 2025
              CategoryNo. of SharesPercentage% Change QoQ
              Promoters30,09,48,72151.82 %0.00
              Pledge5,14,10,00017.08 %0.15
              FII8,34,84,63414.38 %-0.94
              DII15,64,18,91326.93 %0.69
              MF11,01,43,15918.96 %0.75
              Others3,99,49,3556.87 %0.25

            Aurobindo Pharma MF Ownership

            MF Ownership as on 31 July 2025

            View all Mutual Fund Schemes
            Top Searches:
            Aurobindo Pharma News Aurobindo Pharma Quarterly Results Aurobindo Pharma Dividend Aurobindo Pharma Q1 ResultsAurobindo Pharma Q2 ResultsAurobindo Pharma Q3 ResultsAurobindo Pharma Q4 Results

            Aurobindo Pharma F&O Quote

              • Expiry

              Price

              1,047.00-2.20 (-0.21%)

              Open Interest

              1,92,53,30031,900 (0.17%)

              OpenHighLowPrev CloseContracts TradedTurnover (₹ Lakhs)
              1,048.701,057.501,040.501,049.2098610,346.98

              Open Interest as of 08 Sep 2025

              • Type
              • Expiry
              • Strike Price

              Price

              21.15-0.80 (-3.64%)

              Open Interest

              4,40,00043,450 (10.96%)

              OpenHighLowPrev CloseContracts TradedTurnover (₹ Lakhs)
              20.5526.0018.0021.957968,627.46

              Open Interest as of 08 Sep 2025

            Aurobindo Pharma Corporate Actions

            • Meeting DateAnnounced onPurposeDetails
              Sep 10, 2025Aug 12, 2025AGM-
              Aug 04, 2025Jul 23, 2025Board MeetingQuarterly Results & Interim Dividend
              May 26, 2025May 16, 2025Board MeetingAudited Results
              Mar 20, 2025Feb 13, 2025POM-
              Feb 06, 2025Jan 17, 2025Board MeetingQuarterly Results
            • TypeDividendDividend per ShareEx-Dividend DateAnnounced on
              Interim400%4.0Aug 08, 2025Aug 04, 2025
              Interim150%1.5Feb 20, 2024Feb 07, 2024
              Interim300%3.0Nov 20, 2023Nov 02, 2023
              Interim300%3.0Feb 17, 2023Feb 03, 2023
              Interim450%4.5Jun 06, 2022May 20, 2022
            • All TypesEx-DateRecord DateAnnounced onDetails
              BonusJul 20, 2015Jul 21, 2015May 28, 2015Bonus Ratio: 1 share(s) for every 1 shares held
              SplitsFeb 10, 2011Feb 11, 2011Nov 03, 2010Split: Old FV5.0| New FV:1.0
              SplitsOct 23, 2003Oct 31, 2003Aug 09, 2003Split: Old FV10.0| New FV:5.0
              BonusMar 07, 2000Apr 01, 2000Feb 22, 2000Bonus Ratio: 1 share(s) for every 1 shares held
              BonusOct 26, 1998Nov 19, 1998Oct 08, 1998Bonus Ratio: 1 share(s) for every 1 shares held

            About Aurobindo Pharma

            Aurobindo Pharma Ltd., incorporated in the year 1986, is a Large Cap company (having a market cap of Rs 60,641.50 Crore) operating in Pharmaceuticals sector. Aurobindo Pharma Ltd. key Products/Revenue Segments include Pharmaceuticals, Sale of services, Export Incentives and Scrap for the year ending 31-Mar-2025. Show More

            • Executives

            • Auditors

            • MR

              M Ramasubramanian Kumar

              Non Exe.Chairman&Ind.Director
              KN

              K Nithyananda Reddy

              Vice Chairman & Mng.Director
              MM

              M Madan Mohan Reddy

              Whole Time Director
              PS

              P Sarath Chandra Reddy

              Non Executive Director
              Show More
            • Deloitte Haskins & Sells
              BSR & Associates LLP

            Industry

            Pharma - Indian

            Key Indices Listed on

            Nifty Midcap 50, Nifty Midcap 100, Nifty 200, + 32 more

            Address

            Plot No.2,Maitri Vihar,Ameerpet,Hyderabad, Telangana - 500038

            Contact

            info@aurobindo.com

            http://www.aurobindo.com

            More Details

            FAQs about Aurobindo Pharma share

            • 1. What's Aurobindo Pharma share price today and what are Aurobindo Pharma share returns ?
              As on 08 Sep, 2025, 03:59 PM IST Aurobindo Pharma share price is down by 0.38% basis the previous closing price of Rs 1,036. Aurobindo Pharma share price is Rs 1,040.20. Return Performance of Aurobindo Pharma Shares:
              • 1 Week: Aurobindo Pharma share price moved up by 1.48%
              • 3 Month: Aurobindo Pharma share price moved down by 10.41%
              • 6 Month: Aurobindo Pharma share price moved down by 5.21%
            • 2. What is the PE & PB ratio of Aurobindo Pharma?
              The PE ratio of Aurobindo Pharma stands at 17.88, while the PB ratio is 1.86.
            • 3. What are the returns for Aurobindo Pharma share?
              Return Performance of Aurobindo Pharma Shares:
              • 1 Week: Aurobindo Pharma share price moved up by 1.48%
              • 3 Month: Aurobindo Pharma share price moved down by 10.41%
              • 6 Month: Aurobindo Pharma share price moved down by 5.21%
            • 4. What is 52 week high/low of Aurobindo Pharma share price?
              52 Week high of Aurobindo Pharma share is Rs 1,592.00 while 52 week low is Rs 1,010.00
            • 5. What is the market cap of Aurobindo Pharma?
              Aurobindo Pharma share has a market capitalization of Rs 60,414.98 Cr. Within Pharmaceuticals sector, it's market cap rank is 11.

            Trending in Markets

            Top Gainers As on 03:59 PM | 08 Sep 2025

            Suven Pharma 1,012.95
            90.06 (9.76%)
            Guj Mineral Dev.539.15
            30.15 (5.93%)
            Bharat Forge1,202.80
            66.10 (5.82%)
            Ashok Leyland137.29
            6.52 (4.99%)
            JP Power20.02
            0.95 (4.99%)

            Top Losers As on 03:57 PM | 08 Sep 2025

            Amber Enterprises7,473.00
            -320.50 (-4.12%)
            EID Parry1,067.30
            -45.50 (-4.09%)
            Trent5,315.50
            -213.00 (-3.86%)
            Godfrey Philips10,657.00
            -416.00 (-3.76%)
            Coromandel Int.2,185.20
            -72.71 (-3.22%)

            DATA SOURCES: TickerPlant (for live BSE/NSE quotes service) and Dion Global Solutions Ltd. (for corporate data, historical price & volume, F&O data). Sensex & BSE Quotes and Nifty & NSE Quotes are real-time and licensed from BSE and NSE respectively. All timestamps are reflected in IST (Indian Standard Time).

            DISCLAIMER: Any and all content on this website including tools/analysis is provided to you only for convenience and on an “as-is, as- available” basis without representation and warranties of any kind. The content and any output of such tools/analysis is for informational purposes only and should not be relied upon or construed as an investment advice or guarantee for any specific performance/returns advice or considered as recommendation for the purchase or sale of any security or investment. You are advised to exercise caution, discretion and independent judgment with regards to the same and seek advice from professionals and certified experts before taking any decisions.

            By using this site, you agree to the Terms of Service and Privacy Policy.

            Business News›Markets›Stocks›Stock Price Quotes›Aurobindo Pharma Share Price
            The Economic Times
            BrowseCompanies: